Werewolf Therapeutics, Inc.
HOWL
$0.39
$0.001.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 3.20% | -27.27% | |||
| Gross Profit | 463.78% | 27.27% | |||
| SG&A Expenses | 75.03% | 38.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.00% | -4.80% | |||
| Operating Income | 195.22% | 4.80% | |||
| Income Before Tax | 127.12% | -61.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 127.12% | -61.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 127.12% | -61.46% | |||
| EBIT | 195.22% | 4.80% | |||
| EBITDA | 228.26% | 4.99% | |||
| EPS Basic | 127.11% | -60.89% | |||
| Normalized Basic EPS | 191.07% | -9.70% | |||
| EPS Diluted | 126.96% | -42.42% | |||
| Normalized Diluted EPS | 191.07% | -11.56% | |||
| Average Basic Shares Outstanding | 0.00% | 0.35% | |||
| Average Diluted Shares Outstanding | 0.00% | -1.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||